Serplulimab/Trastuzumab plus Intensive Triplet DOS Chemotherapy in First-line HER2-positive Advanced Gastric Cancer (ASTRUM): A Multicenter Phase II Trial with Dynamic Multi-Omics Profiling
Outcomes for HER2-positive advanced gastric cancer remain unsatisfactory. This multicenter phase II trial (NCT05311189) pioneered the first exploration of intensive DOS triplet chemotherapy combined with serplulimab and trastuzumab as first-line therapy for untreated HER2-positive advanced gastric adenocarcinoma. Dynamic multi-omics profiling was further performed to identify biomarkers for durable clinical benefit (DCB). Eligible patients received up to eight cycles of triple combination therapy, followed by maintenance serplulimab plus trastuzumab. The primary endpoint was progression‑free survival (PFS); secondary endpoints included overall survival (OS), objective response rate (ORR), and safety. Exploratory analyses comprised longitudinal tumor and peripheral blood transcriptomics, circulating tumor DNA (ctDNA), and multiplex immunofluorescence. Forty patients were enrolled. At a median follow‑up of 16.5 months, median PFS was 15.7 months (95% CI 6.8-24.7). ORR was 97.3%, including two complete responses. The 12‑month OS rate was 80.5% (95% CI 60.0-91.2). Grade 3-4 treatment‑related adverse events occurred in 40% of patients, with no treatment‑related deaths. Baseline DCB tumors were enriched for adaptive immune signatures, including higher densities of tertiary lymphoid structures, T cells, and B cells within the tumor microenvironment and these patients also showed systemic immune activation in peripheral blood. Conversely, non‑durable benefit (NDB) tumors exhibited pronounced angiogenic, myeloid, and fibroblast predominance. Early clearance of ERBB2 copy‑number alterations in ctDNA was associated with prolonged PFS. Collectively, this novel regimen featuring firstly adopted intensive DOS triplet chemotherapy plus serplulimab and trastuzumab yields robust antitumor activity and favorable tolerability. Baseline immune activation, systemic immune awakening and early molecular response jointly predict DCB, whereas angiogenic‑myeloid‑fibroblast features characterize non‑responders.